We are live on ! Find out more

Tradr 2X Long IBM Daily ETF

IBX

Market cap $52.1M

20.40 USD

+0.20

0.99%

At close Updated Oct 26, 11:30 AM EDT

1 day

0.99%

5 days

17.11%

1 month

31.53%

3 months

34.65%

6 months

-1.31%

Year to date

-13.12%

1 year

-13.12%

5 years

-13.12%

10 years

-13.12%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion Biosystems, Ltd. (ASX: IBX) announced it will resume MagSense® Nanoparticle manufacturing capabilities ahead of its Phase 1b/2 clinical trial and potential commercialization. The company has contracted nanoComposix, a nanoparticle Contract Development and Manufacturing Organization (CDMO). Under the signed agreement, Imagion will provide the proprietary nanoparticle synthesis equipment, software and procedures required for the CDMO to start manufac.

Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--IBX announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA's clearance of IND for a Phase 2 trial.

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion's IND Application for HER2 MagSense® Imaging Agent Phase 2 Clinical Trial Has Cleared FDA Review. Company to proceed with clinical trial.

Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

See News Rankings

Price charts implemented using Lightweight Charts™